$KD

Hagens Berman expands class action against Kyndryl (KD) for allegedly manipulating free cash flow metrics. Stock fell 55% after SEC probe; CFO and General Counsel departed.

Rosen Law Firm filed a class action lawsuit against ImmunityBio ($IBRX), alleging founder Patrick Soon-Shiong materially overstated Anktiva's capabilities, impacting investors.

Rosen Law Firm filed a securities class action against Kyndryl Holdings alleging false disclosures on financials and internal controls, with an April 2026 lead plaintiff deadline.

Class action lawsuit filed against Kyndryl for alleged false financial statements and internal control failures during August 2024-February 2026 period.

Kyndryl faces securities class action lawsuits after disclosing material control weaknesses and executive departures. Stock fell 55% to $10.59; lead plaintiff deadline set for April 13, 2026.

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

Rosen Law Firm urges Kyndryl investors to retain counsel before April 13, 2026 deadline in securities class action over false financial disclosures.

Law firm seeks investors in $KD securities fraud lawsuit, alleging false statements and inadequate financial controls between August 2024 and February 2026.

Kyndryl faces securities fraud lawsuit after CFO departure, SEC investigation into cash practices, and inability to file quarterly reports. Stock plummeted 54.9%.

Rosen Law Firm urges Kyndryl investors to join securities lawsuit alleging false financial statements and internal control deficiencies. Lead plaintiff deadline April 13, 2026.

Kyndryl Holdings faces securities class action lawsuit alleging materially false statements and inadequate internal controls. Lead plaintiff deadline set for April 13, 2026.

Kyndryl faces securities fraud lawsuit over cash management misstatements. Stock crashed 54% after CFO departure and internal control weaknesses disclosed.

Law firm files class action against Kyndryl for alleged securities fraud, false financial statements, and internal control failures affecting investors from August 2024 through February 2026.

Kyndryl ($KD) stock crashed 55% after disclosing internal control weaknesses and executive departures. Class action lawsuits filed; lead plaintiff deadline April 13, 2026.

Saxena White filed expanded securities class action against Kyndryl for allegedly misleading investors on free cash flow metrics across an 18-month period amid governance failures.

Kyndryl faces securities fraud lawsuit after revealing internal control weaknesses and executive departures. Stock plunged 55% to $10.59; investor deadline April 13, 2026.

Shareholder lawsuits target $KD and $QURE over alleged disclosure violations, with lead plaintiff applications due April 13, 2026. Affected investors may pursue recovery.

Four companies face securities fraud lawsuits alleging false business disclosures. Investors have until April 2026 to file lead plaintiff motions.

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against $KD, alleging false financial disclosures and control failures from August 2024 to February 2026.

Rosen Law Firm urges Kyndryl (KD) investors to seek legal counsel by April 13, 2026 deadline in class action alleging false financial statements and control failures.